| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Parathyroid hormone (PTH)/PTH-related peptide receptor (PPR); also known as PTH1R; a class B GPCR that regulates calcium homeostasis and bone remodeling.
|
|---|---|
| ln Vitro |
In HEK 293 cells transfected with the human PPR (EC50 26±14 nM), DPC-AJ1951 TFA causes intracellular Ca2+ mobilization[1][1].
DPC-AJ1951 TFA induces intracellular Ca2+ mobilization in HEK293 cells expressing human PPR with EC50 = 26 +/- 14 nM; functions in ex vivo and in vivo bone resorption assays. |
| ln Vivo |
Characterized in ex vivo bone resorption assays (fetal rat long-bone explants) and in vivo assays; stimulates osteoclast-mediated bone resorption, increases collagen synthesis, and promotes cell proliferation.
|
| Enzyme Assay |
Receptor binding assessed by radioligand competition binding using [125I]PTHrP or [125I]PTH and membranes from cells expressing human PPR; cAMP accumulation measured to confirm functional agonism.
|
| Cell Assay |
HEK293 cells stably transfected with human PPR are treated with DPC-AJ1951 TFA at 1-1000 nM; intracellular Ca2+ mobilization measured using fluorescent Ca2+ indicator dyes (e.g., Fluo-4 AM) on a plate reader.
|
| Animal Protocol |
Fetal rat long-bone explants are cultured with DPC-AJ1951 TFA (1-100 nM) for 24-96 h; bone resorption assessed by measuring calcium release or 45Ca release; in vivo, mice receive IV/SC doses; osteoclast activity measured by histomorphometry.
|
| ADME/Pharmacokinetics |
Limited PK data; as a 14-amino acid peptide, DPC-AJ1951 TFA is susceptible to proteolytic degradation; low oral bioavailability; typically administered via injection for in vivo experiments.
|
| Toxicity/Toxicokinetics |
No dedicated toxicity data; as a peptide agonist of PTH1R, potential adverse effects include hypercalcemia, bone loss with chronic use; for research use only.
|
| References | |
| Additional Infomation |
DPC-AJ1951 TFA is a research peptide tool; not approved for clinical use; no clinical trial status. For research use only in bone metabolism studies.
|
| Molecular Formula |
C78H128F3N23O21
|
|---|---|
| Molecular Weight |
1781.02
|
| Related CAS # |
DPC-AJ1951;943519-33-3
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~56.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5615 mL | 2.8074 mL | 5.6148 mL | |
| 5 mM | 0.1123 mL | 0.5615 mL | 1.1230 mL | |
| 10 mM | 0.0561 mL | 0.2807 mL | 0.5615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
